Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1)
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (9), 4382-4389
- https://doi.org/10.1158/0008-5472.can-06-4124
Abstract
Ral-binding protein 1 (RALBP1) is a stress-responsive and stress-protective multispecific transporter of glutathione conjugates (GS-E) and xenobiotic toxins. It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts. In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma. Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy. Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used. Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells. Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells. RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts. RALBP1 inhibition by anti-RALBP1 IgG was equally as effective as antisense and enhanced CDDP-vinorelbine in lung cancer xenografts. These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.Keywords
Other Versions
This publication has 40 references indexed in Scilit:
- Mitogenic and drug-resistance mediating effects of PKCα require RLIP76Biochemical and Biophysical Research Communications, 2006
- RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migrationThe Journal of cell biology, 2006
- Determinants of differential doxorubicin sensitivity between SCLC and NSCLCFEBS Letters, 2006
- Identification of Membrane-Anchoring Domains of RLIP76 Using Deletion Mutant AnalysesBiochemistry, 2004
- RLIP76 (RALBP1)‐mediated transport of leukotriene C4 (LTC4) in cancer cells: Implications in drug resistanceInternational Journal of Cancer, 2004
- Protein Kinase C–Dependent Increase in Reactive Oxygen Species (ROS) Production in Vascular Tissues of DiabetesJournal of the American Society of Nephrology, 2003
- Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): A novel link between G‐protein and tyrosine kinase signaling and drug resistanceInternational Journal of Cancer, 2003
- Two Distinct 4-Hydroxynonenal Metabolizing Glutathione S-Transferase Isozymes Are Differentially Expressed in Human TissuesBiochemical and Biophysical Research Communications, 2001
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994
- Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein.JCI Insight, 1994